| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
PanCare Health Offers Health Care Services In Multiple Locations, Including Freeport And Bonifay, FL For Urgent Care, Affordable Therapy, And More. Call Today!
Bioprocessing is a Scarborough, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We want to share our innovations with you and learn from your feedback. Help us improve quality and design to make sure your system delivers from day one.
Mary Crowley Medical Research is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.